ArticleMolecules (Basel, Switzerland)2025
Enhanced Encapsulation of Linalyl Acetate in Cyclodextrin-Based Metal-Organic Frameworks for Improved Stability.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficient Encapsulation and Sustained Release of Linalyl Acetate Using Fractal Bimodal Mesoporous Silica.Nanomaterials (Basel, Switzerland) · 2026Article
- Enhancing bioactivity and bioavailability of Limonium bellidifolium via cyclodextrin-based inclusion complexes: a new strategy in drug discovery from halophyte source.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Linalyl acetate (LA), a key volatile component in essential oils, is extensively utilized in fragrance, food, and cosmetic industries. Nevertheless, its practical applications are constrained by rapid evaporation and physicochemical instability. This study developed novel cyclodextrin-metal-organic frameworks (CD-MOFs) crystallized from β-cyclodextrin (β-CD) and γ-cyclodextrin (γ-CD) with potassium hydroxide, demonstrating superior structural properties for LA encapsulation. Through comparative analysis with native CDs, the synthesized CD-MOFs exhibited highly ordered crystalline architectures and uniform morphological characteristics. The LA encapsulation capacity of the γ-CD-MOF was systematically evaluated under different conditions using a three-level factorial design via RSM. Optimization revealed maximum encapsulation efficiency (25.9%) under ideal conditions-an LA:γ-CD-MOF mass ratio of 3.8:1, 60.9 °C incubation temperature, and 49.3 min processing time-representing a 2.39-fold enhancement over conventional CD encapsulation. Thermal stability analysis demonstrated remarkable improvement, with LA-γ-CD-MOF complexes showing an onset decomposition temperature of 215 °C, 135 °C higher than that of free LA. Compared with LA-γ-CD, LA coated with γ-CD-MOFs still retained 55.7% at 80 °C for 75 min, with the release rate reduced by about 45.3%. These findings establish the potential of γ-CD-MOFs as effective carriers for thermolabile and volatile compounds in functional food and cosmetic industries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.